THREE-DIMENSIONAL PRINTING ANTIMICROBIAL PRODUCTS
20230295445 · 2023-09-21
Assignee
Inventors
Cpc classification
B33Y10/00
PERFORMING OPERATIONS; TRANSPORTING
C09D5/14
CHEMISTRY; METALLURGY
C08L55/02
CHEMISTRY; METALLURGY
B29C64/124
PERFORMING OPERATIONS; TRANSPORTING
B29K2105/0035
PERFORMING OPERATIONS; TRANSPORTING
B33Y80/00
PERFORMING OPERATIONS; TRANSPORTING
C09D155/02
CHEMISTRY; METALLURGY
B33Y70/10
PERFORMING OPERATIONS; TRANSPORTING
B29K2055/02
PERFORMING OPERATIONS; TRANSPORTING
International classification
C09D5/14
CHEMISTRY; METALLURGY
B33Y70/10
PERFORMING OPERATIONS; TRANSPORTING
C09D155/02
CHEMISTRY; METALLURGY
Abstract
A method of preparing antimicrobial 3D-printed material with antimicrobial agents integrated with the 3D-printed material. The 3D-printed material fabricated with the method of the present disclosure includes antimicrobial agent (s) fully integrated throughout the product and display antimicrobial effect throughout the product, which is resistant to daily wear and tear.
Claims
1. A method of preparing antimicrobial 3D-printed material, comprising the steps of: a) mixing an antimicrobial agent with a 3D printing resin; b) transforming the combined solution through digital light processing in the 3D printer; and c) printing the material.
2. The method according to claim 1, wherein the 3D-printed material does not contain nanotubes.
3. The method according to claim 1, wherein the antimicrobial agent is in liquid form.
4. The method according to claim 3, the antimicrobial agent is provided in 10% by weight of the resin.
5. The method according to claim 1, wherein the antimicrobial agent is in solid form.
6. The method according to claim 5, the antimicrobial agent is provided in 0.25-1% by weight of the resin.
7. The method according to claim 1, wherein the antimicrobial agent is selected from the group consisting of: polyhexamethylene biguanide (PHMB), chloroxylenol, cetylpyridinum chloride (CPC), cetrimonium bromide (CTAB), zinc oxide, silver oxide, titanium dioxide and combinations thereof.
8. The method according to claim 1, wherein the antimicrobial agent is Polyhexamethylene biguanide (PHMB).
9. The method according to claim 1, wherein the antimicrobial agent is zinc oxide, silver oxide, or titanium dioxide.
10. The method according to claim 7, wherein the antimicrobial agent is a combination of Polyhexamethylene biguanide (PHMB) and zinc oxide.
11. The method according to claim 1, the mixing step is performed using an ultrasonic mixer.
12. The method according to claim 1, wherein a mixing agent is added during the mixing step.
13. The method according to claim 12, wherein the mixing agent is selected from the group consisting of alcohol and Dimethyl sulfoxide (DMSO).
14. The method according to claim 13, wherein the alcohol is 99% ethanol.
15. The method according to claim 12, wherein the mixing agent is added in an amount in the ratio of 1:1 of the antimicrobial agent.
16. The method according to claim 1, wherein the digital light processing is provided by a digital light projector.
17. The method according to claim 1, wherein the resin is ABS based UV sensitive resin.
18. The method according to claim 16, wherein the resin is selected from the group consisting of EPIC, ABS-tough, TOUGH-GRY (e.g. TOUGH-GRY 10), E-PDXY, E-RIGID PU BLACK, E-RIGID PU NATURAL, E-RIGIT PU WHITE, E-SHORE A 40, E-SHORE A 80, LOCTITE 3D 5015 SILICONE E1 CLEAR, E-RIGIDFORM AMBER, ERIGIDFORM CHARCOAL, PREFACTORY HARZ D20 WHITE (ABS FLEX WHITE), ABS HI-IMPACT GRAY and ABS HI-IMPACT BLACK.
19. An antimicrobial 3D-printed material prepared according to the method of claim 1.
20. The antimicrobial 3D-printed material of claim 19, wherein the 3-D printed material does not contain nanotubes.
Description
BRIEF DESCRIPTION OF THE FIGURES
[0025] In order to describe the manner in which the above-recited and other advantages and features of the disclosure can be obtained, a more particular description of the principles briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. Understanding that these drawings depict only exemplary embodiments of the disclosure and are not therefore to be considered to be limiting of its scope, the principles herein are described and explained with additional specificity and detail through the use of the accompanying drawings.
[0026] Preferred embodiments of the present invention will be explained in further detail below by way of examples and with reference to the accompanying figures, in which:-
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0037] Various embodiments of the disclosure are discussed in detail below. While specific implementations are discussed, it should be understood that this is done for illustration purposes only. A person skilled in the relevant art will recognize that other components and configurations may be used without parting from the spirit and scope of the disclosure.
[0038] The disclosed technology addresses the need in the art for 3D-printed products having antimicrobial activities, and methods for preparing the antimicrobial 3D-printed products.
[0039] Referring to the figures,
[0040] In one embodiment, there is provided a method of preparing antimicrobial 3D-printed material, comprising the steps of: [0041] 1. mixing an antimicrobial agent with a 3D printing resin [0042] 2. transforming the combined solution through digital light processing in the 3D printer; and [0043] 3. printing the material.
[0044] In an embodiment, the 3D-printed material is free of nanotubes and/or silver nitrate.
[0045] In an embodiment, the antimicrobial agent is in liquid form and provided in 10% by weight of the resin.
[0046] In an embodiment, the antimicrobial agent is in solid form and provided in 0.25-1% by weight of the resin.
[0047] The antimicrobial agent is a chemical antimicrobial agent that is positively charged as they are particularly suited for killing viruses, as virus shells are negatively charged. Examples of positively charged chemical antimicrobial agents include: Polyhexamethylene biguanide (PHMB), Chloroxylenol, Cetylpyridinum Chloride (CPC), Cetrimonium Bromide (CTAB), Zinc Oxide, Silver Oxide, Titanium dioxide and combinations thereof.
[0048] The antimicrobial agent is transparent such that the agent does not deflect or block light required for DLP 3D printing.
[0049] In an embodiment, the antimicrobial agent is Polyhexamethylene biguanide (PHMB), which may be provided as a solution or in solid form.
[0050] In an embodiment, the antimicrobial agent is zinc oxide, silver oxide, or titanium dioxide.
[0051] In an embodiment, the antimicrobial agent is a combination of Polyhexamethylene biguanide (PHMB) and zinc oxide.
[0052] Optionally, mixing is performed using an ultrasonic mixer.
[0053] In an embodiment, a mixing agent is added to further improve the mixing quality or increase the antimicrobial activity of the 3D printed product. Exemplary mixing agents include alcohol, such as, ethanol, or Dimethyl sulfoxide (DMSO). Preferably, the mixing agent is added in an amount in the ratio of 1:1 of the antimicrobial agent.
[0054] In an embodiment, the mixing agent is 99% ethanol.
[0055] In an embodiment, digital light processing is provided by a digital light projector, and the light beam projected by the digital light projector is reflected by a digital micromirror device (DMD).
[0056] In an embodiment, the resin is ABS based UV sensitive resin, e.g. EPIC, ABS-tough, TOUGH-GRY (e.g. TOUGH-GRY 10), E-PDXY, E-RIGID PU BLACK, E-RIGID PU NATURAL, E-RIGIT PU WHITE, E-SHORE A 40, E-SHORE A 80, LOCTITE 3D 5015 SILICONE E1 CLEAR, E-RIGIDFORM AMBER, ERIGIDFORM CHARCOAL, PREFACTORY HARZ D20 WHITE (ABS FLEX WHITE), ABS HI-IMPACT GRAY, ABS HI-IMPACT BLACK, and the resin is placed in the vat of the 3D printer.
[0057] In an embodiment, the 3D printed material displays antiviral and antibacterial activities for at least 90 days, preferably at least 180 days, and more preferably at least 250 days. A number of technical problems have been solved by the method of the present disclosure: [0058] Method of the present disclosures allows users to prepare products with the desired antimicrobial agents in a flexible manner, as the chemical formulation, ingredients and resins can be easily adjusted. [0059] The use of DLP technique in 3D printing allows the manufacturing of products in an efficient and cost-effective manner, since the method does not require complex and costly nanotechnology. Further, as compared to SLA 3D printing, DLP achieves quicker print times as the DLP printer exposes entire layers at once. [0060] The 3D printed material provides a clear indication to users of the antimicrobial activity of the surfaces, giving comfort to users at the time of pandemic. This is in contrast to traditional antimicrobial coating, as users have no way of knowing whether the area is disinfected at a certain time, due to the loss of activity after treatment over time. [0061] Also, as compared to products with surfaced treated with antimicrobial agents, the core of the 3D-printed materials is expected to exhibit antibacterial and antiviral activities, providing consistent antimicrobial effect even as the object surface progressively wears or is scratched off, which is a common problem seen in products with high usage by the general public. [0062] The method can be used to print handles (e.g., toilet door, exit doors, and recycling boxes) or covers in public areas to avoid contamination. It is expected that the products printed from the 3D printer according to the method of the present disclosure have antibacterial and antivirus features throughout its life cycle. In particular, it is envisaged that the method of the present disclosures can significantly reduce the chance of contact contamination by providing 3D printed door handles and covers that could inactivate virus and bacteria with a corresponding low level of maintenance required. [0063] Apart from the reduction of the risk of disease transmission in public area, the 3D printed material prepared by the method of the present disclosure is particularly suited for medical use, as well as the rehabilitation area, such as the devices to assist patient's mobility, such as walking devices or assistive tools for wheelchairs. Those devices are often needed to be customized and antimicrobial feature would further prevent patients from illnesses.
EXAMPLES
Example 1: Parallel Streak Test
[0064] Tests for two 3D printing materials were conducted to determine the inhibitory effect of a 3D printed material prepared using the method of the present disclosure. Two bacteria —Staphylococcus aureus (S. aureus) (Gram positive) and Klebsiella pneumoniae (K. pneumoniae) (Gram negative)—commonly found in the environment are being tested.
[0065] The testing of antibacterial effect is based on to modified method of AATCC Test Method 147, which is also known as the Parallel Streak test. This method is useful for obtaining a rough estimate of activity in that the growth of the inoculum organism decreases from one end of each streak to the other and from one streak to the next resulting in increasing degrees of sensitivity. The size of the zone of inhibition and the narrowing of the streaks caused by the presence of the antibacterial agent permit an estimate of the residual antibacterial activity after multiple washings (AATCC).
[0066] In this test, ABS based UV sensitive resins were selected and mixed with two exemplary antimicrobial agents (e.g., 10% by weight of Polyhexamethylene biguanide, and 0.25% by weight of zinc oxide) as shown in the Table 1 below.
[0067] The antimicrobial agent was first mixed with 3D printing resin to form a modified resin, and subsequently an ultrasonic mixer was used to remove bubbles from the mixture. The combined solution was then transformed through the digital lighting processing in the 3D printing machine. Details of the 3D printing method and re-hardening process are as summarized below.
TABLE-US-00001 TABLE 1 Re- Ultrasonic hardening Resin Amount UV mixing Process Polyhexamethylene Envision TEC 10% of net Brightness Frequency Otoflash biguanide HTM140V2 weight of the 700 mw/dm.sup.2 22 KHz, heating G171 2X resin power 250 W, 2000 ultrasonic flashes power 140 W ToughGry - 10% of net Brightness Frequency Otoflash 10 weight of the 700 mw/dm.sup.2 22 KHz, heating G171 2X resin power 250 W, 2000 ultrasonic flashes power 140 W EPIC 10% of net Brightness Frequency Otoflash weight of the 700 mw/dm.sup.2 22 KHz, heating G171 2X resin power 250 W, 2000 ultrasonic flashes power 140 W Zinc Oxide Envision TEC 0.25% of net Brightness Frequency Otoflash HTM140V2 weight of 700 mw/dm.sup.2 22 KHz, heating G171 2X resin power 250 W, 2000 ultrasonic flashes power 140 W Envision TEC 0.5% of net Brightness Frequency Otoflash HTM140V2 weight of 700 mw/dm.sup.2 22 KHz, heating G171 2X resin power 250 W, 2000 ultrasonic flashes power 140 W
[0068] The results of the parallel streak test are provided in
TABLE-US-00002 TABLE 2 Test 1 10% Test 2 10% weight of 0.25% 0.5% weight of PHMB weight weight PHMB With Zinc oxide Zinc oxide Control with EPIC Tough Gry Control With HTM with HTM Klebsiella No 2.3 mm 1.8 mm No No No pneumoniae inhibition inhibition inhibition inhibition zone zone zone zone Staphylococcus No 4.2 mm 6 mm No Slight Slight aureus inhibition inhibition inhibition inhibition zone zone zone zone
Example 2: Surface Abrade Test
[0069] A surface abrade test was performed to determine the antimicrobial activity of the internal part of the 3D-printed product. PHMB (10% by weight) and Zinc Oxide (2.5% by weight) was added to HTM 140 resin, and printed by the method of the present disclosure using DLP technology, and the surface of the printed material was scratched away using a cutter before subjecting the samples to the modified AATCC Test Method 147 as described above. The abraded surface was placed downward (touching the petri dish).
[0070] After culturing Klebsiella pneumoniae with the sample, an inhibition width of 0.067 was observed, demonstrating the antimicrobial effect of the inner portion of the 3D-printed material on Klebsiella pneumoniae.
Example 3: Parallel Streak Test of Samples Formed with Mixing Agent
[0071] Experiment was repeated using ABS-tough, which is another 3D printing resin that has some inherent basic antibacterial function. The resin was mixed with significantly smaller amount of water base PHMB (1% of net weight).
[0072] Instead of using an ultrasonic mixer, alcohol was as the mixing agent to improve the quality of the mixing. The modified AATCC Test Method 147 was repeated and the results show that the 3D-printed samples display stronger antibacterial effects Staphylococcus aureus, while all samples do not allow bacterial to grow over the samples. This is an indication of effective antibacterial function of the surface of the sample.
[0073]
TABLE-US-00003 TABLE 3 Sample SA Inhibition KP Inhibition Sample Information Scrape Width (mm) Width (mm) F Control No treatment 0.25 0, no bacteria crossing F014-1 0.14% wt, N 1.7 0.06 1600 mg/l F014-2 1:1 ethanol Y 0, no bacteria 0.06 crossing F035-1 0.35% wt N 0.25 0.13 F035-2 1:1 ethanol Y 0.06 0, no bacteria crossing F100-1 1.00% wt N 1.69 0, no bacteria crossing F100-2 1:1 ethanol Y 0.69 0, no bacteria crossing
[0074] Based on the result of the control sample, it is observed that the plastic itself exhibits some antibacterial activity, potentially due to the residue of alcohol at the printing base after the printing out the treatment samples. Additionally, it is observed that non-scraped samples have better antibacterial activity than scraped samples, and the antibacterial effect on S. aureus is significantly improved by the use of alcohol as a mixing agent.
Example 4: Parallel Streak Test of Samples Formed with Mixing Agent and Powder Form of PHMB
[0075] Example 3 was repeated with samples prepared with PHMB powder instead of PHMB solution, with all the other parameters remain the same. The results are shown in Table 4 below and also in
[0076] As compared to the test result of Example 3, the abraded samples (as shown in the left photos) are found to display stronger inhibition effect than the samples prepared with PHMB solution. It shows that the PHMB powder mixed inside the material is able to provide an enhanced effect to the cracked surface. Such results are favourable to the public application, when the product surfaces could be easily scratched by thousands of users' nails, keys, and other tools. The inhibition effects will remain strong despite normal wear.
TABLE-US-00004 TABLE 4 SA Inhibition KP Inhibition Sample Width (mm) Width (mm) ABS Tough PHMB Powder 6.5 8.5 0.3% wt, abraded ABS Tough PHMB Powder 3.8 0.3 0.3% wt, not abraded
[0077] These experimental result confirm that the 3D printing method of the present disclosure allows full integration of antimicrobial function of an antimicrobial agent into the 3D printing materials, allowing the provision of antimicrobial function in a more long-lasting manner as compared to other techniques involving spray coating the surface of the product. As would be expected by those skilled in the art, since the antimicrobial agent is fully integrated into the product, the antimicrobial effect would remain despite “wear and tear” due to daily usage. Therefore, the uncertainty of ineffectiveness can be minimized. Table 4 below provide a comparison of the antimicrobial approaches in public area with high frequency skin contacts, further supporting the advantageous of the method of the present disclosure.
TABLE-US-00005 TABLE 5 Cleaning with disinfection Antimicrobial agents coating spray Printed Product Effectiveness Until next 90 days (or Whole product continuity contacts until the life cycle of virus surface is (years) worn off) Effectiveness Good High High Clear indication Uncertain Uncertain Certain of anti-microbial effect Chances of High Low Low contamination to cleaner Mass customization Nil Yes Yes Cost Low Moderate High Maintenance effort High Medium Low
[0078] The above embodiments are described by way of example only. Many variations are possible without departing from the scope of the invention as defined in the appended claims. Although a variety of examples and other information was used to explain aspects within the scope of the appended claims, no limitation of the claims should be implied based on particular features or arrangements in such examples, as one of ordinary skill would be able to use these examples to derive a wide variety of implementations. Further and although some subject matter may have been described in language specific to examples of structural features and/or method steps, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to these described features or acts. For example, such functionality can be distributed differently or performed in components other than those identified herein. Rather, the described features and steps are disclosed as examples of components of systems and methods within the scope of the appended claims.